Altria Group, Inc. MO currently trades at a forward 12-month price-to-earnings (P/E) ratio of 11.01 — a notable 24% discount compared to the Zacks Tobacco industry average of 14.49. This valuation gap becomes even more pronounced when compared to key competitors like Philip Morris International Inc. PM (P/E of 21.95) and Turning Point Brands, Inc. TPB (P/E of 16.39). While a low P/E ratio might catch the eye of a value investor, in Altria's case, it has been more of a reflection of persistent investor concerns rather than a hidden gem waiting to be discovered. With a Value Score of C, MO appears less attractive from a valuation standpoint.

Image Source: Zacks Investment Research

The stock price performance tells a similar story. Over the past 12 months, Altria stock has returned 37.1%, significantly underperforming the industry average of 54.3%. In the same time frame, Philip Morris has delivered an impressive 65.8% return, while Turning Point Brands surged a remarkable 106.1%. Even shares of British American Tobacco p.l.c. BTI have surged 45.2% in this time frame. This consistent underperformance implies more than just cyclical weakness — it points to core issues holding the stock back compared to more agile peers like Philip Morris and Turning Point Brands.

MO’s One-Year Price Performance Vs. Peers

Image Source: Zacks Investment Research

MO Struggles With Cigarette Volumes and Shifting Demand

At the heart of Altria's ongoing struggles is the decline in cigarette consumption. With smoking rates at historic lows, the company’s core customer base is shrinking. Although the company still holds a dominant share in the traditional cigarette market with its Marlboro brand, shipment volumes are falling, putting sustained pressure on both revenues and long-term growth prospects.

Younger demographics are turning away from traditional cigarettes due to health-conscious lifestyles, making Altria’s core tobacco products less relevant in a market shifting toward smoke-free alternatives. Compounding the challenge is the rapid rise of illicit e-vapor products. Weak enforcement has led to an unexpected surge in cross-category movement, with adult smokers turning to illegal vapor alternatives at a faster pace, further eroding Altria’s shares. Beyond consumer behavior, it faces mounting regulatory pressures. The U.S. Food and Drug Administration (FDA) has tightened restrictions on marketing practices. These headwinds create additional costs and uncertainty, particularly around market access. 

These trends have taken a toll on Altria's financial performance, particularly its Smokeable Products segment. Over the past few quarters, this core business unit has reported consistent revenue declines. In the fourth quarter of 2024, domestic cigarette shipments declined 8.8%, reflecting both the broader industry downturn and Altria’s loss in retail share. Much of this weakness is tied to economic pressure on adult consumers, who are scaling back spending amid persistent discretionary income challenges.